Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.

Anti-cancer drugs - 1 Apr 2015

Massari Francesco, Ciccarese Chiara, Bimbatti Davide, Fantinel Emanuela, Modena Alessandra, Simbolo Michele, Brunelli Matteo, Artibani Walter, Martignoni Guido, Scarpa Aldo, Tortora Giampaolo

Abstract excerpt

Sunitinib represents a reasonable therapeutic option for first-line treatment of poor-risk metastatic renal cell carcinoma and the treatment should aim at the delicate balance between managing side effects to improve the toxicity profile and patient compliance to treatment while maintaining anticancer efficacy. Achievement of a complete response, although rare, is possible, even in poor-risk patients. Treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Kidney Neoplasms

Share to Pyrroles

Share to Remission Induction

Share to Sunitinib

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Identifiers

PMID: 25569703
DOI: 10.1097/CAD.0000000000000208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.PMID 25569703Read ↗

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Semantic proximity Read ↗

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.Semantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].Semantic proximity Read ↗

Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.Semantic proximity Read ↗

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Semantic proximity Read ↗

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Semantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinomaSemantic proximity Read ↗

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.Semantic proximity Read ↗

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.